Free tool
FAERS Monitor: Xenleta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211672 or its brand name (Xenleta, Lefamulin Acetate). Reports on generic versions are filed under their own applications.
Reports
17
Serious
3
18% of reports
Hospitalization
1
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea7
- vomiting4
- nausea3
- product use in unapproved indication3
- abdominal discomfort2
- palpitations2
- pneumonia2
- abdominal pain upper1
- cold sweat1
- death1
- drug ineffective1
- feeling abnormal1
- gastrointestinal disorder1
- headache1
- hypersensitivity1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 8 |
| 2021 | 8 |
| 2022 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,142 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cold sweat | 1 | 70.2 | 10.5 | 17 |
| palpitations | 2 | 21.1 | 5.7 | 21 |
| product use in unapproved indicationSignal | 3 | 15.0 | 5.4 | 27 |
| abdominal discomfort | 2 | 14.8 | 4.0 | 14 |
| gastrointestinal disorder | 1 | 13.8 | 2.1 | 3 |
| diarrhoeaSignal | 7 | 13.4 | 7.6 | 71 |
| vomitingSignal | 4 | 10.5 | 4.5 | 26 |
| pneumonia | 2 | 7.6 | 2.1 | 6 |
| hypersensitivity | 1 | 6.7 | 1.0 | 1 |
| abdominal pain upper | 1 | 6.0 | 0.9 | 1 |
| feeling abnormal | 1 | 5.2 | 0.8 | 0 |
| nauseaSignal | 3 | 4.7 | 1.7 | 6 |
| headache | 1 | 2.0 | 0.3 | 0 |
| death | 1 | 1.4 | 0.2 | 0 |
| drug ineffective | 1 | 0.9 | 0.1 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.